Gilead and Eisai Enter Into Agreement in Japan for the CoPromotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib Pending Regulatory Approval

Agreement Extends to Additional Potential Indications for Filgotinib Including Ulcerative Colitis Crohns Disease and Psoriatic Arthritis Gilead Sciences Inc. Nasdaq GILD and Eisai Co. Ltd. Tokyo Japan announced today that Gilead Sciences K.K. Tokyo Japan ...